DATE: October 19, 2017
TIME: 08:00am PDT, 11:00am EDT
Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T cell gene delivery still remain in order for this therapy to become a standard of care practice. In this webinar, we will highlight the different viral and non-viral delivery approaches used in T cell engineering for cell and gene therapy applications including:
Learning Objectives:
Cancer Research
Immunology
Cell Biology
Cancer Therapeutics
Biotechnology
Molecular Biology
Cell Culture
Cancer Diagnostics
Oncology
Biomarkers
Gene Expression
Immuno-Oncology
Genetics
Clinical Research
Drug Discovery
North America56%
Europe28%
Asia6%
South America3%
Oceania2%
Africa2%
Website Visitors100%
Student17%
Scientist15%
Research Scientist13%
Executive12%
Facility/Department Manager11%
Medical Doctor/Specialist6%
Post Doc5%
Medical Laboratory Technician4%
Educator/Faculty3%
Marketing/Sales3%
Clinical Laboratory Scientist3%
Lab Management2%
Engineer2%
QC/QA2%
Biologist2%
Chemist1%
Consultant1%
Academic Institution9%
Biotech Company8%
Research Institute5%
Clinical Laboratory3%
Hospital3%
Life Science Company3%
Government2%
Pharmaceutical Company2%
Medical Center1%
Ambulatory Care1%
Consultant1%
Contract Research Organization (Cro)1%
Industrial Company1%
Medical School1%
Other2%